CD274 and cancer: In the 4T1 model, however, mice receiving DAC either alone or in combination with PeptiCRAd significantly enhanced MHC class I (Figure 4G) and PD-L1 (Figure 4H) expression on cancer cells (EP-CAM+, CD3−), in contrast with the previous B16-OVA animal experiment.